|
|
|
|
|
|
|
28.04.25 - 14:33
|
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025 (GlobeNewswire EN)
|
|
|
SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA....
|
|
|
|
|
|
|
06.03.25 - 14:33
|
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025 (GlobeNewswire EN)
|
|
|
SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes....
|
|
|
24.02.25 - 14:33
|
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors (GlobeNewswire EN)
|
|
|
SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke's commercial strategy and growth potential....
|
|
|
|
|
|
|
03.12.24 - 14:33
|
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® (GlobeNewswire EN)
|
|
|
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company's robust intellectual property estate for its innovative GIMOTI® (metoclopramide) nasal spray....
|
|
|
|
|
|
|
|
|
|
|
22.10.24 - 14:33
|
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors (GlobeNewswire EN)
|
|
|
SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company's Board of Directors effective October 18, 2024. This appointment fulfills a condition set as part of the company's most recent financing by Nantahala Capital Management....
|
|
|
01.08.24 - 08:09
|
XFRA : EV0: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
EVOKE PHARMA INC.DL-,0001 EV0 US30049G3020 BAW/UFN...
|
|
|
|
|
31.07.24 - 16:50
|
XFRA : ISIN CHANGE (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
US30049G2030 Evoke Pharma Inc. 31.07.2024 US30049G3020 Evoke Pharma Inc. 01.08.2024 Tausch 12:1...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
